67
Mostly True
United States
The website discusses an early trial of a pancreatic cancer mRNA vaccine showing lasting results, highlighting the survival of patients like Donna Gustafson. It mentions the challenges of treating pancreatic cancer and the potential of personalized mRNA vaccines as a breakthrough.
The claims regarding the pancreatic cancer mRNA vaccine and related statistics are largely supported by credible evidence. The early trial results for the mRNA vaccine show promise, with multiple sources confirming lasting immune responses. The survival statistics for pancreatic cancer are well-documented, with authoritative sources confirming the low survival rates and the limited operability of cases. The launch of a Phase 2 trial by Genentech and BioNTech is also well-supported by official announcements. Overall, the evidence strongly supports the factual accuracy of these claims, with the exception of the personalized vaccine claim, which was not verified in this context.
Individual Claims
76
Mostly True
Health
Pancreatic cancer mRNA vaccine shows lasting results in an early trial.
The claim is supported by multiple sources indicating that early trials of a personalized mRNA vaccine for pancreatic cancer have shown promising and lasting results. Sources like Let's Win Pancreatic Cancer and Oncology Times report on the sustained immune activity observed in small patient groups, suggesting potential effectiveness. However, these are early trials, and larger studies are needed to confirm these findings.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
76
Evidence Summary
2 web sources corroborate early trial results showing promise for mRNA vaccine.
85
True
Health
Less than 13% of people diagnosed with pancreatic cancer live for more than five years.
The claim is strongly supported by authoritative sources such as Cancer Research UK and the Hirshberg Foundation, which confirm that the five-year survival rate for pancreatic cancer is around 13%. This statistic is widely recognized and reported in the medical community.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
95
Source Quality Weight
25
Llm Reasoning Score
90
Llm Reasoning Weight
25
Weighted Total
85
Evidence Summary
Multiple authoritative sources confirm the 13% survival rate.
78
Mostly True
Health
Only about 20% of pancreatic cancer cases are operable.
The claim is supported by evidence from the American Cancer Society and other reputable sources, which state that fewer than 20% of pancreatic cancer cases are operable. This is consistent with the understanding that most cases are diagnosed at an advanced stage where surgery is not feasible.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
78
Evidence Summary
Multiple sources confirm that about 20% of cases are operable.
9
False
Health
The mRNA vaccines are personalized for each individual using genetic material taken from their unique tumor cells.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
None
Web Consensus Weight
0
Source Quality Score
None
Source Quality Weight
0
Llm Reasoning Score
-1
Llm Reasoning Weight
100
Weighted Total
9
Evidence Summary
None
66
Mostly True
Health
Six years after treatment, Gustafson and six others who responded to the treatment are still alive.
The claim is partially supported by evidence indicating that some patients have shown long-term survival after treatment with the mRNA vaccine. However, specific details about the exact number of survivors and their conditions are less clear, requiring more precise data for full verification.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
70
Web Consensus Weight
50
Source Quality Score
65
Source Quality Weight
25
Llm Reasoning Score
60
Llm Reasoning Weight
25
Weighted Total
66
Evidence Summary
Some evidence supports long-term survival, but details are limited.
88
True
Health
Genentech and BioNTech have launched a larger Phase 2 clinical trial for the pancreatic cancer vaccine.
The claim is strongly supported by multiple sources, including official announcements from BioNTech and Genentech, confirming the launch of a Phase 2 clinical trial for the pancreatic cancer vaccine. This trial is well-documented and aligns with ongoing research efforts.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
95
Source Quality Weight
25
Llm Reasoning Score
90
Llm Reasoning Weight
25
Weighted Total
88
Evidence Summary
Multiple sources confirm the launch of a Phase 2 trial by Genentech and BioNTech.
